Author: Phil McCracken

Phil McCracken covers Washington from the stress fracture outward. His reporting studies the crack between public virtue and private invoicing, where patriotic speeches, donor checks, midnight amendments, and think-tank PDFs all meet for drinks and pretend it is civic duty. McCracken follows the money, the lobbyists, the favors, the sudden changes of heart, and the miraculous policy positions that bloom shortly after a fundraiser. He is less impressed by flag pins than by loopholes, delays, carve-outs, and the small-print blessings that make corruption look like procedure. His beat is rot in the broad civic sense: not just crime, but structure; not just scandal, but design; not just who got caught, but who built the room where getting caught barely matters. He cracks the door open and lets the fluorescent shame leak out. Categories: Politics, Corruption, Justice, Business, U.S.
  • |

    Public Grants, Private Tollbooth: Who Pays Twice for Xtandi?

    ByPhil McCracken

    At my invoice desk, the Xtandi money trail arrives wearing a lab coat and leaves in a limousine. The complaint is straightforward: public funding helped support UCLA-linked research, while commercialization and patent control became associated with Astellas and Pfizer. Then patients encountered annual U.S. price claims reaching roughly $160,000 to $180,000. That is a remarkable billing arrangement—taxpayers help finance the road, private interests control the toll gate, and the patient gets charged for driving on it.

    Not every stage of Xtandi’s development can be reduced to one public grant or one private decision, and a list price is not the same as every patient’s bill. But the public-return question remains as stubborn as a bad line item: when public science helps move an essential medicine forward, what does the public receive besides another invoice? Innovation may begin as public service, yet somehow ends as private property with a collections department. Follow the invoice long enough and it reaches the same destination: the patient, standing at the pharmacy counter with the receipt and no lobbyist’s expense account.

  • |

    The Drug-Price Mystery Has a Lobbying Budget

    ByPhil McCracken

    Patients receive a prescription bill written like a ransom note from an accountant, while the pharmaceutical industry’s Washington invoice arrives in plain English. Bloomberg Government reported that PhRMA spent $7.4 million lobbying in the second quarter of 2026, bringing its year-to-date total to $19.6 million. I have seen less money spent renovating an entire Capitol Hill office, although admittedly fewer people were trying to influence the rulebook.

    That spending does not, by itself, prove that lobbying caused any particular drug price or defeated any particular proposal. It does reveal something less mysterious: the trade group representing major pharmaceutical interests has a very clear budget for being present while everyone else debates why medicine costs so much. When an industry spends millions to participate in the policy conversation, “expertise” starts looking a lot like a reserved seat with better coffee.

    The timing is the whole money trail. Washington continued debating Medicare negotiation, most-favored-nation pricing, and other proposals aimed at lowering costs. Those are policy arguments, not settled outcomes, and they deserve scrutiny on their details. But patients are routinely told that drug pricing is too complex for ordinary people to understand, just as the people affected by the bill are asked to wait outside the room while well-funded representatives explain the machinery.

    That is the access economy in its natural habitat: the public gets a maze of rebates, formularies, negotiations, and carefully polished explanations; lobbyists get calendars, meetings, and a professional vocabulary for turning private interests into public homework. The pharmaceutical lobbying total reported by Bloomberg Government is not the entire industry’s spending, and it is not evidence of illegal conduct. It is simply a large, legible number attached to an argument that is often presented as impossibly complicated.

    So Washington keeps searching for the missing answer to drug prices. Meanwhile, the money trail has already found the billing department. Patients get the mystery, lobbyists get the appointment calendar, and taxpayers get another explanation for why reform remains under review.

    Sources

  • |

    The Pentagon’s $7 Billion Software Subscription Comes With a Free Accountability Question

    ByPhil McCracken

    Phil McCracken looks at a possible $7 billion Pentagon software commitment the way a diner waitress looks at a fake coupon: polite, tired, and already checking the fine print. The Defense Department can call the Oracle agreement a savings plan because it replaces scattered software purchases with one enterprise deal. That may reduce duplication. It does not magically reduce the number of questions attached to a very large bill.

    Federal News Network reports that the agreement could run for 10 years and reach up to $7 billion. The first five-year period is valued at $3.3 billion, with a possible extension worth another $3.6 billion. The Pentagon projects at least $441 million in savings through consolidation. Important word there: projects. That is a forecast, not a check cleared by reality.

    There is nothing inherently foolish about buying software in a more organized way. A government that discovers it has been purchasing the same digital wrench from several counters might reasonably try using one counter. But procurement efficiency and public accountability are different departments, even if both occupy the same enormous federal building. A cheaper arrangement should be demonstrated through verified costs, usable performance, renewal terms, and transparent oversight—not merely announced with the confidence of a man who has found a coupon for 40 percent off a yacht.

    The concentration matters because one vendor could receive a decade-long revenue runway while taxpayers are asked to trust the savings math. That is not evidence of wrongdoing, favoritism, or an illegal contract. It is evidence that a large, centralized commitment deserves more than a victory lap. When government replaces several smaller purchases with one giant agreement, it may simplify billing while increasing dependence on a single supplier. Follow the invoice, then follow the exit door. Someone should know what leaving would cost.

    Washington has apparently placed the projected savings in one column, the potential $7 billion commitment in another, and left the accountability column for the public to fill in with a pencil. The Pentagon may have cleaned up the invoice. Taxpayers still need to know whether the savings survive contact with delivery, renewals, upgrades, and the fine print. A tidier bill is not proof of accountable value; it is simply a tidier bill waiting for an audit.

  • |

    The Fund Is Dead. The Tax Break Survived.

    ByPhil McCracken

    Washington has discovered a new form of accounting: cancel the giant government fund, keep the boss’s special protection, and announce that the ledger is clean. Acting Attorney General Todd Blanche formally terminated the proposed $1.8 billion Anti-Weaponization Fund, according to the Associated Press. AP also reported that no money had been transferred and no claims had been paid. So taxpayers did not already write the full check. The question is what stayed on the invoice after the check was stamped void.

    The answer, according to AP’s reporting on Blanche’s written order, is a retroactive tax-audit protection for Donald Trump, his two sons, and the Trump Organization. Republican senators had tied ending the proposed fund to Blanche’s confirmation negotiations. The fund went away. The Trump-specific protection did not.

    That is not exactly a refund. It is more like Capitol Hill billing: cross out the scary line item in thick black ink, leave the executive’s personal coupon attached, and call the procurement officer a hero. A judge had rejected the tax-audit provision as improper self-dealing, AP reported. That is reported legal context, not a license for anyone to declare criminal intent from the comedy desk.

    But ordinary taxpayers understand the basic imbalance without a forensic accountant. The public-facing liability can disappear before money moves, while a politically valuable exception survives in writing. The proposed fund is dead; the protection is still breathing. Why do regular people get the audit, the paperwork, and the waiting-room chair while politically connected beneficiaries get retroactive shelter? Washington can cancel the scary check whenever the cameras arrive. The real test is whether it also removes the coupon.

  • |

    We Fund the Science. They Set the $3.95 Million Price.

    ByPhil McCracken

    I followed the Kebilidi invoice and found NIH’s NCATS on the public-science side, PTC Therapeutics at the commercial finish line, and a stated price of $3.95 million waiting like it had its own congressional parking space. That does not mean public research invented every molecule or erased the company’s costs. It does mean taxpayers and patients deserve a seat at the pricing table when public support helped move a rare-disease therapy from scientific risk toward treatment.

    One-time gene therapies are complex and expensive; nobody is asking the lab to accept payment in inspirational refrigerator magnets. But complexity cannot be the magic word that makes public investment disappear from the conversation. The public helped build the runway, while private billing arrived dressed as the sole owner of aviation. Follow the invoice: government may not have created every part of Kebilidi, but families should not be treated like silent partners who receive only the receipt. Fair pricing and fair taxes are the minimum decent terms.

  • |

    The Miracle Arrives With a $3.2 Million Invoice

    ByPhil McCracken

    Here is the money trail presented by the scenario: children’s-hospital and academic micro-dystrophin research tied to Nationwide Children’s Hospital moves into Sarepta’s private commercialization pipeline, and the number waiting at the end is $3.2 million. Nationwide is presented as receiving licensing and royalty revenue; families and payers are presented as facing the cost. That is a remarkable invoice-routing system: the science gets described as a shared triumph, while the people who need it are treated like they wandered into the pricing meeting without a badge.

    Profit is not the villain. Pretending the public-private pipeline ends at “innovation” is. If the figure and licensing arrangement are accurate as presented, the contradiction is hard to miss: the breakthrough gets inspirational music, the commercial deal gets revenue, and the family gets a financial document written in the ancient language of “please indicate which organ you’d like to sell first.” Nobody has to oppose useful medicine or licensing to ask why the people carrying the medical and financial risk get no meaningful seat at the pricing table.

  • |

    Chicago Finds $424 Million Under the Stadium Cushion

    ByPhil McCracken

    Phil McCracken here, following the invoice through Chicago’s latest stadium miracle. The Chicago Fire stadium can be privately financed on paper while roughly $424 million to $425 million in public tax-increment financing supports the roads, river-wall repairs, Metra improvements, parking garage and surrounding site work needed to make the project function. The stadium line is private; the “please build everything around the stadium” line is public. That is not the same as taxpayers buying seats, but it is taxpayers helping create the conditions under which the private owner can sell them.

    The reports from WTTW and NBC Chicago describe a roughly $750 million stadium backed by Fire owner Joe Mansueto, alongside the public TIF package for the surrounding infrastructure. Officials can therefore say taxpayers are not funding the stadium itself while public money helps pay for access, parking, transit improvements and the riverbank. In ordinary household accounting, that is called “the expensive part we moved to another envelope.”

    Here is the Phil McCracken audit: if a billionaire buys the jersey, who builds the locker room, paves the route to it and repairs the riverbank? Chicago’s technical distinction separates paying for the building from paying to make the building viable, as if a house were private because the owner bought the couch while the neighborhood paid for the street. Public improvements can serve broader needs, and that deserves an honest accounting—not a magic trick with a TIF label.

    The public deserves to know exactly which benefits are general infrastructure and which are a welcome mat for one private development. Because when the invoice is split this neatly, the private owner gets the stadium, the public gets the debt-shaped participation trophy, and everyone is told not to confuse the two. Follow the invoice long enough and the money trail eventually stops at the locker room door.

  • |

    Your Grant Has Been Sent to Political Review

    ByPhil McCracken

    Phil McCracken here, standing at the federal grant counter with a project proposal in one hand and the correct political facial expression in the other. The Office of Management and Budget says its proposed government-wide grant rule is about transparency, accountability, oversight, and reducing burdens. Admirable words. They are the sort of words that arrive wearing a clean tie while the fine print follows behind carrying a clipboard.

    The concern is not that public money should escape scrutiny. Taxpayers deserve to know where their money goes, and grant recipients should be able to explain the work, the budget, and the public benefit. The concern is who gets to define “accountability” when the definition can bend toward the administration’s priorities. A Senate opposition letter warns that vague standards and presidential policy goals could give political officials greater influence over grant decisions. That is less neutral review and more audition panel with a federal seal.

    Roll Call reported that the proposal could require approval from senior political appointees for competitive awards, while OMB reviews nearly 497,000 public comments before deciding whether to issue a final rule. The report also said the changes could affect up to $1 trillion or more in annual grant funding across the government. Those are not pocket-change consequences. That is the national budget walking into a room where someone may ask whether the applicant’s research has demonstrated sufficient enthusiasm for the current mood.

    Critics have not shown that political appointees have already overridden specific grants under this proposal, and the rule is not final. But the warned-about effect is plain enough: an agency could say it is adding oversight while creating another political checkpoint between a meritorious application and the money Congress provided. The public pays for the program, professionals evaluate the work, and then an official may get to inspect the project for ideological indigestion. Follow the invoice and you eventually find the taxpayer waiting outside the office.

    The new application checklist practically writes itself: describe the project, attach the budget, identify the public need, and reassure the federal wallet that your work will not cause a flare-up in the prevailing political theology. Accountability should mean showing citizens how funds are awarded and spent—not teaching applicants which powerful people must be flattered before the door opens. Public money belongs to the public, even when the approval desk has better carpeting.

  • |

    California’s Diaper Deal Came With a No-Bid Receipt

    ByPhil McCracken

    Phil McCracken here, following the invoice until it stops pretending to be a scavenger hunt. California’s $6.2 million agreement with Baby2Baby was described by state officials in language that made the procurement sound competitive, while CBS News reported that the state’s own contract database labeled it noncompetitive. That is not a bidding contest so much as paperwork standing in the driveway wearing a referee shirt.

    The public purpose matters: helping families obtain diapers is not the scandal, and CBS did not report that Baby2Baby committed wrongdoing. The issue is how California explained the award. An information-gathering process was presented as competition, even though the database reportedly showed no competitive bid. Public benefit is not a magic eraser for procurement questions. Taxpayers deserve to know who was invited, what was compared, and why this vendor received the money.

    Then came the records request. CBS reported that the requested documents took 66 days to arrive. If the process was clean and straightforward, the receipt should not require a small expedition through the bureaucratic jungle, complete with snacks and a compass. Transparency is not an optional garnish added after the public has already paid the bill; it is how ordinary people distinguish an efficient emergency purchase from a convenient procurement story.

    CBS also reported more than two dozen similar budget exemptions covering over $1 billion. That broader pattern does not prove every agreement was improper, but it does show why language matters. Once “noncompetitive” starts getting dressed up as “competitive,” the public is left auditing adjectives instead of contracts. Meanwhile, FACT requested that the state auditor investigate the administration’s diaper contracts; that is an accountability demand, not a completed audit or finding.

    California’s diaper deal may have met a real need. It still deserved a clear bidding record, timely disclosures, and an honest label. The contract was not necessarily competing in a contest; it was competing for Most Technically Competitive-Adjacent Paperwork. Follow the invoice long enough and the money trail eventually admits what the vocabulary was trying to hide: a public need can be urgent without making public scrutiny inconvenient.

  • |

    Skysona and the $3 Million Toll Booth

    ByPhil McCracken

    I audit public-private invoices for a living, and Skysona arrives looking like a federal infrastructure project with a very expensive toll booth. The premise is straightforward: NIH support, academic medical centers, and basic research helped build the gene-therapy road, while bluebird bio brought a finished treatment to market with a $3 million price tag. Rare-disease therapies are complex, and private development matters. Fine. Complexity is not a magic eraser for the public role.

    The money trail deserves more than an innovation ribbon-cutting. If taxpayers and public institutions carried part of the long, uncertain research burden, patients and families are entitled to ask what public return comes with the private invoice. Nobody is claiming bluebird bio did nothing; the question is who absorbed the early risk and who gets the reward when science becomes a product. Taxpayers helped pave the road. Calling the toll booth innovation does not make the receipt disappear.

End of content

End of content